MRVI Q3 2022 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$191M-6.6% YoY

Gross Profit

$153M80.0% margin

Operating Income

$117M61.1% margin

Net Income

$44M23.3% margin

EPS (Diluted)

$0.76

QoQ Revenue Growth

-21.2%

Cash Flow

Operating Cash Flow

$110M

Free Cash Flow

$104M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$1.4B

Stockholders' Equity

$504M

Cash & Equivalents

$617M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$191M	$205M	-6.6%
Gross Profit	$153M	$173M	-11.3%
Operating Income	$117M	$155M	-24.8%
Net Income	$44M	$54M	-17.6%

Revenue Segments

Nucleic Acid Production Segment

$175M91%

Biologics Safety Testing Segment

$16M9%